Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma Academic Article uri icon

Overview

MeSH Major

  • Benzoquinones
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • Melanoma

abstract

  • At this dose and schedule of 17-AAG, the effects of 17-AAG on RAF kinase expression were short-lived, and no objective antimelanoma responses were seen. Future trials in melanoma should focus on a more potent hsp90 inhibitor or a formulation that can be administered chronically for a more prolonged suppression of the MAPK pathway.

publication date

  • December 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2629404

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-08-1002

PubMed ID

  • 19088048

Additional Document Info

start page

  • 8302

end page

  • 7

volume

  • 14

number

  • 24